Bristol Myers Squibb CEO Chris Boerner sits down with CNBC's Angelica Peebles at the American Society of Clinical Oncology's ...

Bristol Myers Squibb has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Camzyos heart drug for adolescents with symptomatic obstructive ...

Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to ...

Most Undervalued Stocks to Invest In. On May 20, 2026, Bristol-Myers Squibb Company (NYSE:BMY) announced a strategic ...

With an annual dividend yield of 4.25%, Bristol-Myers Squibb Company (NYSE:BMY) is included among the 12 Best Dividend Stocks ...

By Michael Erman May 29 (Reuters) - Bristol Myers Squibb said on Friday that its experimental oral drug mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients whose ...

The latest medicines from Bristol Myers Squibb (BMY +0.47%) were the driving force behind the company's considerable share price gain on Thursday. The pharmaceutical company's fir ...

Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Camzyos (mavacamten) as a potential treatment for ...

Bristol Myers Squibb (BMY) stock is in focus as the company's multiple myeloma drug combo lifts cancer-free survival by over 50% in a late-stage trial. Read more here.

Houston is one of three sites the global pharma company is considering.

C4 Therapeutics (CCCC) stock gains as Bristol-Myers Squibb's (BMY) multiple myeloma drug, similar to company's lead asset, generates strong trial data. Read more here.